James Hart, MD
Psychiatry · Franklin, TNNPI 1215915871
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,095 of the $53,093 with a category attached, or 83.1%. Teva Pharmaceuticals USA, Inc. accounts for 85.2% of it on its own, with 23 other manufacturers making up the rest. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 494 payments — averaging $107.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$45K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$976
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$974
- Johnson & Johnson$968
- Neurocrine Biosciences, Inc.$751
- plus $3K from 18 others
Across 141 payments — averaging $1228.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$87K
- Teva Pharmaceuticals USA, Inc.$36K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$12K
- Neurocrine Biosciences, Inc.$10K
- Vanda Pharmaceuticals Inc.$10K
- Supernus Pharmaceuticals, Inc.$8K
- plus $10K from 4 others
What the payments were for
- Speaking & faculty fees$44,09583%
- Travel & lodging$4171%
- Food & beverage$8,39916%
- Education$1820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 66 | $45,258 |
| Vanda Pharmaceuticals Inc. | 50 | $1,195 |
| Alkermes, Inc. | 54 | $976 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $974 |
| Johnson & Johnson | 63 | $968 |
| Neurocrine Biosciences, Inc. | 38 | $751 |
| Otsuka America Pharmaceutical, Inc. | 33 | $484 |
| Sunovion Pharmaceuticals Inc. | 24 | $465 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $353 |
| Lundbeck LLC | 19 | $342 |
| Avanir Pharmaceuticals, Inc. | 15 | $283 |
| E.r. Squibb & Sons, L.L.C. | 10 | $270 |
| AbbVie(2 entities) | 11 | $182 |
| Merck | 10 | $152 |
| Axsome Therapeutics, Inc. | 6 | $109 |
| Eisai Inc. | 5 | $79 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| Noven Therapeutics, LLC | 3 | $52 |
| Almatica Pharma LLC | 3 | $42 |
| Luye Pharma (USA) Ltd. | 1 | $28 |
| Harmony Biosciences LLC | 1 | $24 |
| Novartis | 1 | $20 |
| Indivior Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,093 in reported general payments places this provider in the 95th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $203,707 |
| Invega SustennaPaliperidone Palmitate | 18 | $58,062 |
| BelsomraSuvorexant | 96 | $41,900 |
| CaplytaLumateperone Tosylate | 24 | $39,536 |
| VraylarCariprazine Hcl | 24 | $37,407 |
| FanaptIloperidone | 25 | $34,338 |
| Lurasidone Hcl | 30 | $22,224 |
| TrintellixVortioxetine Hydrobromide | 22 | $12,137 |
| Clozapine | 136 | $12,022 |
| Aripiprazole | 155 | $8,807 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 100 | $6,639 |
| Asenapine Maleate | 29 | $6,612 |
| Quetiapine Fumarate | 286 | $6,362 |
| Fluphenazine Hcl | 21 | $5,796 |
| Ziprasidone Hcl | 47 | $4,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $751 | $203,70725 claims |
| Johnson & JohnsonInvega Sustenna | $968 | $58,06218 claims |
| MerckBelsomra | $152 | $41,90096 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $974 | $39,53624 claims |
| AbbVieVraylar | $182 | $37,40724 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,195 | $34,33825 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $353 | $12,13722 claims |
| Almatica Pharma LLCSertraline Hcl | $42 | $1,422153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Franklin
- Sricharan MoturiFranklin$82K
- William BellFranklin$10K
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Michelle CochranNashville$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.